Yelak Biru | CureTalks
Yelak is an Information technology director for a fortune 50 global CPG company. He is also myeloma patient and advocate. Diagnosed with stage III myeloma at a young age of 25, Yelak was given 2-3 years to live. Two decades later, he continues to share the hope of living with myeloma by respecting the past, understanding the present and being energized by the future. Yelak is a member of the International Myeloma Foundation board of directors, a past speaker at EHA on Relapsed and Refractory myeloma, a facilitator at smartpatients.com, a member of the Global Myeloma Action network and an attendee of ASH since 2006. You can follow Yelak on twitter @NorthTxMSG
Related Talks
High Risk Myeloma Treatment Options
Myeloma is classified as high-risk based on presence of cytogenetic abnormalities and poor treatment outcomes. Despite many new drugs and drug combinations being…
Myeloma: 2016 Year in Review and Outlook for 2017
The treatment options for myeloma continued to evolve in 2016 with new agents, immune based therapies and repurposing of existing approved agents. High-dose…
Understanding iSTOPMM: Iceland Screens, Treats, or Prevents Multiple Myeloma with Dr. Sigurour Yngvi Kristinsson
iStopMM initiative may be one of most important events in modern day myeloma care. As part of the iStopMM study, 140,000 Icelanders over…
History and Future Initiatives for High Risk Smoldering Myeloma Cure
For this second talk in our high risk smoldering myeloma series, we have Prof. Jesus San Miguel from University of Navarra, Spain discuss…
Understanding ASCENT Clinical Trial for High Risk Smoldering Myeloma Patients
This is the first of a 3 part series of talk on high risk smoldering myeloma and its treatments. Smoldering multiple myeloma (SMM)…